Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Is Paperwork Suffocating British Clinical Research?
Concerns are being raised by a growing number of British academics that bureaucratic overload is stifling their ability to undertake clinical research, compromising the future of this activity in the UK, and ultimately doing patients a disservice. The issues are discussed in a Special Report in the August edition of The Lancet Oncology, written by freelance journalist Adrian Burton.
generic viagra online
Study Highlights Massive Imbalances In Global Fertilizer Use
Synthetic fertilizers have dramatically increased food production worldwide. But the unintended costs to the environment and human health have been substantial. Nitrogen runoff from farms has contaminated surface and groundwater and helped create massive "dead zones" in coastal areas, such as the Gulf of Mexico. And ammonia from fertilized cropland has become a major of air pollution, while emissions of nitrous oxide form a potent greenhouse gas.
News of the day
Studies Examine Morning Sickness Drug, Progesterone Use To Prevent Premature Birth
The following summarizes news coverage on two pregnancy-related studies. ~ Morning sickness: The commonly prescribed heartburn drug metoclopramide -- sold generically and under the brand-names Reglan, Octamide and Maxolon -- can be used to treat morning sickness without harming the health of the fetus, according to a study published on Thursday in the New England Journal of Medicine, Time reports. The drug, which also has anti-nausea properties, is not FDA-approved for use in pregnant women in the U.S., though it is commonly prescribed in European and other countries to treat morning sickness (Park, Time, 6/10). According to the Los Angeles Times, U.S. physicians occasionally prescribe metoclopramide to treat severe morning sickness cases. The new study found that there were no statistically significant differences between infants born to women who took metoclopramide and those who did not. Researchers said that the findings "provide reassurance regarding the safety of metoclopramide for the fetus when the drug is given to women to relieve nausea and vomiting during pregnancy." The study involved 81,703 births among women enrolled in Israel"s largest health HMO, including 33,458 who used the drug (Maugh, Los Angeles Times, 6/11). Jennifer Niebyl, a professor of obstetrics and gynecology at the University of Iowa, said, "There are very few drugs approved for use in the first trimester of pregnancy. But this study could lead to metoclopramide getting approved to treat morning sickness because this is good data with big numbers" (Time, 6/10).~ Progesterone: The hormone progesterone was not effective at preventing premature births among women pregnant with twins, despite evidence suggesting its effectiveness at preventing premature births in single pregnancies, according to a University of Edinburgh study published in the journal Lancet, Reuters reports. Multiple pregnancies have a larger health risk for women and significantly increase the likelihood of miscarriage, premature birth and long-term health problems. The study involved 500 women who took either progesterone or a placebo daily for 10 weeks. Although previous studies have shown that progesterone might prevent premature birth in certain high-risk pregnancies, the new findings show the treatment did not reduce the likelihood of premature delivery or a fetus dying in utero in twin pregnancies. Twenty-five percent of women delivered or had a fetus die before 34 weeks in the progesterone group, compared with 20% in the placebo group (Kahn, Reuters, 6/10).
Cardiovascular

University Of Miami Researchers Demonstrate How Stem Cell Line Regenerates New Cardiac Cells

As the field of stem cell based therapies has progressed, there have been numerous questions about the exact way one of the most promising lines of adult stem cells works to repair damaged heart muscle. Although cells obtained from adult bone marrow are proving to be useful to treat heart disease, there has been a major controversy over whether they are true stem cells capable of forming new heart muscle. Cardiologists at the University of Miami Miller School of Medicine have definitively shown that mesenchymal stem cells from bone marrow do in fact form new heart muscle and blood vessels, leading to major degrees of tissue repair in hearts damaged by a heart attack. Their findings have been published in the August 3 issue of the Proceedings of the National Academy of Sciences. Under the leadership of Joshua M. Hare, M.D., director of the Interdisciplinary Stem Cell Institute at the Miller School, a team of physician-scientists has demonstrated how allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy. "This evidence that these cells form both heart and blood vessel cells is major proof that the cells are true stem cells and our findings support their ongoing use in clinical trials," says Hare. Until now scientists have argued whether mesenchymal stem cells work as stem cells or just manufacture growth factors, delivering materials that have a healing effect on the heart. The new research by the Miller School team answers this question. The findings are relevant to patients as these cells are being tested in clinical trials at the Miller School. Two of the most promising candidates for cell-based therapies are autologous whole bone marrow cells, cells taken from the same person"s body, and mesenchymal stem cells (MSCs), which can be taken from several tissue s. One attractive element of MSCs is their ability to differentiate into a variety of cell types. Ongoing current research includes clinical trials involving MSCs that are both autologous and allogeneic, from another donor. Hare and his team -- which includes Alan Heldman, M.D., professor of medicine in the Cardiovascular Division at the Miller School, Ian McNiece, Ph.D., director of experimental and clinical cell based therapies at the Interdisciplinary Stem Cell Institute, and Juan Pablo Zambrano, M.D., assistant professor of medicine in the Cardiovascular Division -- have already blazed a trail in the field of stem cell research. They are currently engaged in two clinical trials involving the extraction and injection of mesenchymal stem cells in the treatment of cardiac failure. McNiece says the result of this trial "provides insights into the mechanism of repair by stem cells and validates the potential of these stem cells which we are using in ongoing clinical trials." For this study, the team of 12 Miller School researchers began with the theory that mesenchymal stem cells have the ability to become implanted and differentiate within infarcted (or scarred) myocardium, damaged heart tissue. Using animal models, the scientists injected mesenchymal stem cells or a placebo into the subjects, used magnetic resonance imaging (MRI) to track the heart"s healing, and then employed state-of-the-art microscopy to determine the fate of the injected cells with markers of cardiac, vascular muscle and endothelial lineage. What the team found was that the MSCs implanted into the infarct areas, differentiated into cardiomyocytes, heart tissue, and persisted within the heart for months following injection. The mesenchymal stem cells also generated new small and large blood vessels. In animals that were given mesenchymal stem cells, there was a reduction in the amount of scar tissue, increased blood flow to the area, and very importantly a restoration of cardiac function. "What we showed here," says Heldman, "is that the stem cells we injected into the heart muscle actually became part of the new heart tissue; the stem cells turned into both heart muscle cells and blood vessel cells." Hare says "this is the first and definitive demonstration that the cells we are using actually generate new missing cells." Zambrano says it is gratifying to be able to prove that "stem cell therapy does work, and to contribute to the science of a new era in the management of heart diseases." In October 2007, Hare was the first in the nation to win approval from the FDA to initiate a clinical trial injecting autologous mesenchymal stem cells for the treatment of heart failure. The randomized, double-blind study has doctors injecting either low-dose MSCs, high-dose MSCs or placebo into patients undergoing heart surgery. In another study, the Transendocardial Autologous Cells in Ischemic Heart Failure Trial (TAC-HFT), Miller School physicians have been the first in the nation to use a spiral shaped catheter to deliver either bone marrow cells, mesenchymal cells or a placebo to patients. With this latest discovery, the Miller School team of stem cell researchers continues to set themselves apart in this burgeoning field. Hare says the unique feature of the Interdisciplinary Stem Cell Institute program is the parallel relationship between research in the lab and clinical trials. "Our research facilitates the work that we"re doing in the human population." Heldman adds that these findings "add another element to the story of how stem cells work, and why we hope that our unique approach to delivering them to the heart will result in significant benefit for those who have suffered a heart attack." University of Miami Miller School of Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009